Challenges with Fixing the Ceiling Price Under the 2013 DPCO
The Department of Pharmaceuticals (DoP) has directed the NPPA to adopt the correct methodology in all such cases of calculating the ceiling price of scheduled formulations like ciprofloxacin 500 mg and ciprofloxacin 250 mg tablets as per para 4 (i) of DPCO, 2013 and provisions of existing Schedule-I by including market shares of only
NBB Asks Commerce for Rigorous Review of Argentina’s Biodiesel Subsidies
The Coalition asks Commerce to review all of Argentina’s actions since January 2017 relating to the provision of below-market priced soybeans to the biodiesel industry through high export taxes. Commerce invited the comments following a November 19 meeting with National Biodiesel Board (NBB) representatives.
DoP asks companies to revise MRP of drugs on which GST rates have been
As per the DoP order, “In this regard, reference is invited to the O.M. No. 25(5)/2014/Div-V/NPPA dated April 13, 2016 issued by the National Pharmaceutical Pricing Authority (NPPA) which contains detailed guidelines for compliance of revised prices by manufacturers or marketing companies.
DoP clarifies on NPPA’s price-capping powers, under PMO supervision
Under Para 31, of DPCO, 2013, DoP can review the orders of NPPA and in such case the government orders prevail. The OMs (office memoradums) referred by you are review orders by the government (DoP) under Para 31 of DPCO, 2013 and not be treated as setting limits to powers of NPPA,” Singh told The Indian Express.
DoP junks Skymap Pharma review plea against NPPA for Fluconazole Tablets
New Delhi: In a major setback to Skymap Pharmaceuticals Limited, the Department of Pharmaceuticals (DoP) has rejected the review application filed by the drugmaker against a notification issued by the National Pharmaceutical Pricing Authority (NPPA) for fixing the retail price of Fluconazole Tablets 300mg.
